CSPC Pharmaceutical Group Ltd. has obtained approval from China’s National Medical Products Administration (NMPA) to initiate clinical trials with the company’s selective 5-HT2A receptor agonist, SYH-2056 tablets, for the treatment of depression.
Rivo Bio Inc. has disclosed compounds acting as 5-HT2A receptor agonists reported to be useful for the treatment of depression, schizophrenia and anxiety disorders.
2A Biosciences Inc. has described phenethylamines acting as 5-HT2A receptor agonists reported to be useful for the treatment of psychiatric, neurodegenerative, neurodevelopmental, inflammatory and eye disorders.
Atai Therapeutics Inc. has patented new 5-HT2A receptor agonists reported to be useful for the treatment of substance abuse and dependence, treatment-resistant depression, major depression, anxiety, eating, obsessive-compulsive and stress disorder.
Gilgamesh Pharmaceuticals Inc. has identified phenalkylamine compounds acting as 5-HT2A receptor agonists reported to be useful for the treatment of psychiatric disorders.
2A Biosciences Inc. has synthesized tryptamine derivatives acting as 5-HT2A receptor agonists reported to be useful for the treatment of psychiatric, neurodegenerative, neurodevelopmental, inflammatory and eye disorders.
Researchers from Engrail Therapeutics Inc. recently described the pharmacological characterization of ENX-105, a new class of molecule that combines 5-HT1A/2A receptor agonism with D2/3 receptor antagonism, to be used for its antianhedonic and antipsychotic effects.
Neushen Therapeutics Inc. has synthesized 5-HT2A receptor agonists reported to be useful for the treatment of depression, schizophrenia, anxiety and post-traumatic stress disorder.
